My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Results: 1 to 20 of 144

1.

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, Streuli CH.

Breast Cancer Res. 2009;11(3):R41. Epub 2009 Jun 29.PMID: 19563669 [PubMed - indexed for MEDLINE]Related articlesFree article

2.

X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).

Ng CP, Bonavida B.

Mol Cancer Ther. 2002 Oct;1(12):1051-8.PMID: 12481428 [PubMed - indexed for MEDLINE]Related articlesFree article

3.

A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.

Bockbrader KM, Tan M, Sun Y.

Oncogene. 2005 Nov 10;24(49):7381-8.PMID: 16044155 [PubMed - indexed for MEDLINE]Related articles

4.

Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.

Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR.

Mol Cancer Ther. 2008 Jan;7(1):38-47.PMID: 18202008 [PubMed - indexed for MEDLINE]Related articlesFree article

5.

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.

Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A.

Mol Cancer Ther. 2007 Mar;6(3):957-66. Epub 2007 Mar 5.PMID: 17339366 [PubMed - indexed for MEDLINE]Related articlesFree article

6.

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.

Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L.

Oncogene. 2008 Aug 28;27(37):5019-32. Epub 2008 May 12.PMID: 18469855 [PubMed - indexed for MEDLINE]Related articles

7.

Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.

Menendez JA, Vellon L, Lupu R.

Ann Oncol. 2005 Aug;16(8):1253-67. Epub 2005 May 3.PMID: 15870086 [PubMed - indexed for MEDLINE]Related articlesFree article

8.

A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS, Xu L.

BMC Cancer. 2009 Nov 6;9:392.PMID: 19895686 [PubMed - indexed for MEDLINE]Related articlesFree article

9.

Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.

Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Saitou Y, Sugimoto K, Nakano T.

Oncol Rep. 2005 Nov;14(5):1311-6.PMID: 16211302 [PubMed - indexed for MEDLINE]Related articles

10.

Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy.

Yang L, Cao Z, Yan H, Wood WC.

Cancer Res. 2003 Oct 15;63(20):6815-24.PMID: 14583479 [PubMed - indexed for MEDLINE]Related articlesFree article

11.

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.

Cancer Res. 2006 Feb 1;66(3):1640-7.PMID: 16452223 [PubMed - indexed for MEDLINE]Related articlesFree article

12.

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S.

Cancer Res. 2001 Jun 15;61(12):4892-900.PMID: 11406568 [PubMed - indexed for MEDLINE]Related articlesFree article

13.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.PMID: 16887935 [PubMed - indexed for MEDLINE]Related articlesFree article

14.

Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.

Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N.

Cancer Res. 2005 Dec 1;65(23):11018-25.PMID: 16322251 [PubMed - indexed for MEDLINE]Related articlesFree article

15.

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.

Int J Mol Med. 2007 Jul;20(1):3-10. Review.PMID: 17549382 [PubMed - indexed for MEDLINE]Related articles

16.

FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, Lam EW.

Int J Oncol. 2009 Jul;35(1):57-68.PMID: 19513552 [PubMed - indexed for MEDLINE]Related articles

17.

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.PMID: 14751502 [PubMed - indexed for MEDLINE]Related articles

18.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.PMID: 17686159 [PubMed - indexed for MEDLINE]Related articlesFree article

19.

Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.

Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP.

Mol Cancer Ther. 2005 Mar;4(3):435-42.PMID: 15767552 [PubMed - indexed for MEDLINE]Related articlesFree article

20.

Cytoprotective effects of IAPs revealed by a small molecule antagonist.

Galbán S, Hwang C, Rumble JM, Oetjen KA, Wright CW, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Duckett CS.

Biochem J. 2009 Feb 1;417(3):765-71.PMID: 18851715 [PubMed - indexed for MEDLINE]Related articlesFree article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed
Write to the Help Desk